Skip to main
INSM
INSM logo

Insmed (INSM) Stock Forecast & Price Target

Insmed (INSM) Analyst Ratings

Based on 31 analyst ratings
Buy
Strong Buy 39%
Buy 55%
Hold 3%
Sell 3%
Strong Sell 0%

Bulls say

Insmed Inc. has identified a patient population of 500,000 to 1 million diagnosed patients for its products, with significant market growth potential due to misdiagnosis rates in related diseases. The company is projecting full-year 2025 global revenue for its commercial product ARIKAYCE in the range of $405 million to $425 million, while the anticipated launch of Brensocatib shows promise for reaching peak sales of approximately $8.2 billion due to high physician demand. Additionally, Insmed's expansion of its commercial infrastructure, including the addition of 120 sales representatives and plans for further market access improvements, combined with potential label expansions for its existing products, suggests a robust pipeline that could deliver substantial financial upside.

Bears say

Insmed Inc faces significant challenges that contribute to a negative outlook, including the risks associated with unexpected safety events, efficacy concerns, and the potential for regulatory hurdles impacting their drug development pipeline. The company reported substantial net losses of $235.5 million for 4Q24 and $913.8 million for FY24, which raises concerns about its financial stability and ability to fund ongoing research and operational expenses. Furthermore, the uncertain market dynamics, potential delays in product launches, and the looming threat of competition and generic entrants could severely hinder the company's revenue generation potential.

Insmed (INSM) has been analyzed by 31 analysts, with a consensus rating of Buy. 39% of analysts recommend a Strong Buy, 55% recommend Buy, 3% suggest Holding, 3% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Insmed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Insmed (INSM) Forecast

Analysts have given Insmed (INSM) a Buy based on their latest research and market trends.

According to 31 analysts, Insmed (INSM) has a Buy consensus rating as of Jul 10, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $72.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $72.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Insmed (INSM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.